Drawing inspiration from the crossroads of technology and healthcare, Axiles Bionics, based in Brussels, is advancing its ambition to elevate prosthetic solutions. The firm has finalized the first €6 million segment of an €8 million Series A funding, supporting its goal to redefine how prosthetic technology enhances the lives of amputees. The company is a spin-off from Brubotics at Vrije Universiteit Brussel, and it aims to revolutionize mobility solutions through its leading-edge products.
Earlier reports have highlighted Axiles Bionics’ steady progress in integrating robotics with human body mechanics. Since its inception in 2019, the company has made strides with Lunaris, a product distinguished for its natural gait mimicry and adaptability. Over time, its development has consistently aligned with the broader evolution of AI and biomechanics in healthcare, continuing to gather clinical approval and international interest.
How Will the New Funds Be Utilized?
The obtained funding primarily aims to enhance the international reach of Lunaris, the advanced biomimetic prosthetic foot, and support the development of future bionic devices. The company claims Lunaris integrates mechanical adaptability and embedded systems, currently used in clinics across several countries to aid mobility. This financial injection not only facilitates expansion but also emboldens the company’s pursuit of new technologies at the confluence of robotics and prosthetics.
What Does the Future Hold for Bionic Feet?
Axiles Bionics’ current focus remains on developing sophisticated robotic feet that simulate natural walking. Lunaris, their flagship product, is certified by both the FDA and CE, marking a significant milestone in replicating authentic locomotion patterns. Its rising clinical adoption signals a growing acceptance and need for such innovative alternatives to standard prosthetics in the healthcare domain.
Founded by Stefan Yee, the PE Group spearheaded the funding round, remarking:
“Axiles Bionics is setting a new benchmark in robotic prosthetics. With Lunaris already demonstrating clinical, regulatory, and initial commercial success, and a disruptive bionic technology on the horizon, Axiles is well-positioned to scale globally and transform the quality of life for amputees worldwide.”
Concurrently, the EIC Fund’s involvement underscores Europe’s commitment to nurturing health tech advancements.
Pierre Cherelle, Axiles Bionics’ CEO, envisioned a forward-looking approach, saying:
“We envision a future where advanced bionics become standard, enhancing lives with superior mobility, health, and wellbeing. This funding is a vote of confidence in our vision, our team, and the patients we serve.”
The company anticipates this investment will propel its pipeline of technologies further, aiming to reshape the landscape of prosthetic technology globally.
The financial backing by PE Group and significant entities like the EIC Fund and Finance&Invest.brussels demonstrates a strategic intent to fill financing gaps while paving the way for technological innovations. Each of these entities plays a critical role in bolstering Axiles Bionics’ vision and operational growth, ensuring a supportive ecosystem for sustainable development.
Axiles Bionics is well-positioned to make a lasting impact on the prosthetic industry through strategic expansion initiated by this funding. Lunaris sets an advanced standard for biomimetic prosthetics, and as clinical use becomes widespread, demand from patients and healthcare professionals continues to grow. The involvement of prominent investors highlights the remarkable potential within the European health technology sector. These collaborative efforts promise to accelerate Axiles Bionics’ ambitious roadmap, driving forward the advancement of bionic solutions for enhanced mobility and quality of life.
